SAREPTA THERAPEUTICS, INC. Other Nonrecurring (Income) Expense
SAREPTA THERAPEUTICS, INC. (SRPT) reported Other Nonrecurring (Income) Expense of $246.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherNonrecurringIncomeExpense · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. other nonrecurring (income) expense for the quarter ending 2026-06-30 was $246.00K, a 57.07% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. other nonrecurring (income) expense for the quarter ending 2026-03-31 was -$1.16M, a 453.80% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. other nonrecurring (income) expense for the quarter ending 2025-12-31 was -$338.00K, a 452.08% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. other nonrecurring (income) expense for the quarter ending 2025-09-30 was -$702.00K.
- SAREPTA THERAPEUTICS, INC. other nonrecurring (income) expense for fiscal 2025 was -$1.94M.
- SAREPTA THERAPEUTICS, INC. other nonrecurring (income) expense for fiscal 2024 was -$60.00K.
- SAREPTA THERAPEUTICS, INC. other nonrecurring (income) expense for fiscal 2023 was -$910.00K.
- SAREPTA THERAPEUTICS, INC. other nonrecurring (income) expense for fiscal 2022 was -$6.92M.
| Period end | Other Nonrecurring (Income) Expense 3 month | Other Nonrecurring (Income) Expense 3 month as first filed | Other Nonrecurring (Income) Expense 6 month | Other Nonrecurring (Income) Expense 6 month as first filed | Other Nonrecurring (Income) Expense 9 month | Other Nonrecurring (Income) Expense 9 month as first filed | Other Nonrecurring (Income) Expense 12 month | Other Nonrecurring (Income) Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $246.00K 10-Q · filed 2026-08-05 | -$918.00K 10-Q · filed 2026-08-05 | -$1.26M derived: sum of 3 quarters · filed 2026-08-05 | -$1.96M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$1.16M 10-Q · filed 2026-05-06 | -$1.50M derived: sum of 2 quarters · filed 2026-05-06 | -$2.20M derived: sum of 3 quarters · filed 2026-05-06 | -$1.63M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$338.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$1.04M derived: sum of 2 quarters · filed 2026-03-02 | -$467.00K derived: sum of 3 quarters · filed 2026-08-05 | -$1.94M 10-K · filed 2026-03-02 | ||||
| 2025-09-30 | -$702.00K 10-Q · filed 2025-11-06 | -$129.00K derived: sum of 2 quarters · filed 2026-08-05 | -$1.60M 10-Q · filed 2025-11-06 | $296.00K derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $573.00K 10-Q · filed 2026-08-05 | -$573.00K 10-Q · filed 2025-08-06 | $902.00K 10-Q · filed 2026-08-05 | -$902.00K 10-Q · filed 2025-08-06 | $998.00K derived: sum of 3 quarters · filed 2026-08-05 | $741.00K derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $329.00K 10-Q · filed 2026-05-06 | $425.00K derived: sum of 2 quarters · filed 2026-05-06 | $168.00K derived: sum of 3 quarters · filed 2026-05-06 | $288.00K derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $96.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$161.00K derived: sum of 2 quarters · filed 2026-03-02 | -$41.00K derived: sum of 3 quarters · filed 2026-03-02 | -$60.00K 10-K · filed 2026-03-02 | -$2.85M 10-K · filed 2025-02-28 | |||
| 2024-09-30 | -$257.00K 10-Q · filed 2025-11-06 | -$3.14M 10-Q · filed 2024-11-06 | -$137.00K derived: sum of 2 quarters · filed 2025-11-06 | -$156.00K 10-Q · filed 2025-11-06 | -$1.96M 10-Q · filed 2024-11-06 | -$793.00K derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2024-06-30 | $120.00K 10-Q · filed 2025-08-06 | $268.00K 10-Q · filed 2024-08-07 | $101.00K 10-Q · filed 2025-08-06 | $1.18M 10-Q · filed 2024-08-07 | -$536.00K derived: sum of 3 quarters · filed 2026-03-02 | -$961.00K derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2024-03-31 | $19.00K 10-Q · filed 2025-05-06 | $912.00K 10-Q · filed 2024-05-01 | -$656.00K derived: sum of 2 quarters · filed 2026-03-02 | -$1.08M derived: sum of 3 quarters · filed 2026-03-02 | -$927.00K derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2023-12-31 | -$675.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$1.10M derived: sum of 2 quarters · filed 2026-03-02 | -$946.00K derived: sum of 3 quarters · filed 2026-03-02 | -$910.00K 10-K · filed 2026-03-02 | $617.00K 10-K · filed 2024-02-28 | |||
| 2023-09-30 | -$425.00K 10-Q · filed 2024-11-06 | -$271.00K derived: sum of 2 quarters · filed 2024-11-06 | -$235.00K 10-Q · filed 2024-11-06 | -$1.32M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-06-30 | $154.00K 10-Q · filed 2024-08-07 | -$131.00K 10-Q · filed 2024-08-07 | -$894.00K derived: sum of 3 quarters · filed 2025-02-28 | -$695.00K derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-03-31 | -$285.00K 10-Q · filed 2024-05-01 | -$1.05M derived: sum of 2 quarters · filed 2025-02-28 | -$849.00K derived: sum of 3 quarters · filed 2025-02-28 | -$5.52M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | -$763.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$564.00K derived: sum of 2 quarters · filed 2025-02-28 | -$5.24M derived: sum of 3 quarters · filed 2025-02-28 | -$6.92M 10-K · filed 2025-02-28 | ||||
| 2022-09-30 | $199.00K 10-Q · filed 2023-11-01 | -$4.47M derived: sum of 2 quarters · filed 2023-11-01 | -$6.16M 10-Q · filed 2023-11-01 | |||||
| 2022-06-30 | -$4.67M 10-Q · filed 2023-08-02 | -$6.36M 10-Q · filed 2023-08-02 | ||||||
| 2021-12-31 | -$936.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |